Ruiming Xinyao Asset Profile

= Subscriber Access Only

You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.

Year established

2018

Location

Suzhou Jiangsu China

Primary Industry

Pharmaceuticals

About

Based in Suzhou, China, and established in 2018, Ruiming Xinyao operates as a pharmaceutical company that focuses on developing small molecule new drugs for the treatment of ophthalmic diseases. The company's team members are from pharmaceutical companies, such as Novartis and Alcon, who have experience in new drugs development and drug launches. The company's products lines covered the fields of ophthalmology vascular lesions and ophthalmology neurological lesions. The ophthalmology vascular lesions include Age-related wet macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema. The ophthalmology neurological lesions include glaucoma. The form of drug delivery is eye drop, which replaced the previous injection into the vitreous. The company plans to use the series B funding to apply for the Investigational New Drug (IND), product clinical testing, and introduce new projects.

Current Investors

Korea Investment Partners, Sangel Capital, Topping Capital

Request a demo to show more

Primary Industry

Pharmaceuticals

Sub Industries

Molecular Science, Genetics & Gene Therapy, Healthcare, Optometrists & Opticians Products and Services, Pharmaceutical Research & Development

Verticals

HealthTech

Company Stage

Series B

Total Amount Raised

Subscriber access only

Time to go Pro

Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.